available for iOS, Android & web
June 07, 2011
Novartis has received clearance in Europe to market its eye drug Lucentis for macular oedema secondary to retinal vein occlusion, a disease than can cause severe damage to the retina, visual impairment and ultimately blindness.
International Clinical Researcher of the Year 2016
Last chance to enter!
PharmaTimes 2015 Copyright | RSS Feed Subscriptions